BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:In the wake of the FDA Modernization Act and translational rat
 es of cancer drugs into the clinic at just 20%\, it is critical that onco
 logy scientists invest in more translational and predictive models to de-
 risk the validation of novel targets\, predict therapeutic response\, and
  support biomarker discovery.\n\nThe 12th Annual Tumor Models Boston Summ
 it is the only industry-led meeting uniting 200+ industry experts from ph
 arma\, biotech\, academic KOLs and preclinical CROs to delve into the lat
 est case studies in leveraging PDX models\, genetically engineered mouse 
 models\, advanced 3D in vitro models and more. Join industry leaders deve
 loping teams in preclinical\, translational\, pharmacology\, discovery\, 
 pharmacodynamics\, toxicity and biology to optimize and implement more tr
 anslatable oncology models.\n\nURLs:Tickets: https://go.evvnt.com/2397551
 -2?pid=185Brochure: https://go.evvnt.com/2397551-3?pid=185\n\nTime: 8:00 
 AM - 4:10 PM\n\nSpeakers: Alexander Adler\, Principal Scientist and Resea
 rch Associate\, Regeneron Pharmaceuticals Inc\, Alina Ainbinder\, Princip
 al Scientist\, Takeda Pharmaceuticals Co. Ltd.\, Bin Xie\, Director of Im
 muno-Oncology\, Shanghai LIDE Biotech.\, Co.Ltd.\, Colles Price\, Princip
 al Scientist\, Takeda Pharmaceuticals Co. Ltd.\, Deepali\, Sawant\, Senio
 r Principal Scientist\, Amgen Inc.\, Emily Mason-Osann\, Senior Scientist
 \, AstraZeneca\, Francesca Barone M.D.\, Ph.D.\, Chief Scientific Officer
 \, Candel Therapeutics\, Hongyu Xue\, Director In Vivo Pharmacology\, Onc
 ology Research\, Bayer\, Jing Jiao\, Senior Principal Scientist\, Sanofi\
 , Justine Roderick-Richardson\, Scientist\, AstraZeneca\, Katja Mohrs\, P
 rincipal Scientist\, Regeneron Pharmaceuticals Inc\, Ludovic Bigot\, Proj
 ect Manager\, Institut Gustave Roussy\, Mark Wood\, Former Senior Scienti
 st - Research and Pharmacology\, Vertex Pharmaceuticals\, Michael Buckenm
 eyer\, Postdoctoral Fellow\, National Cancer Institute\, Pengyu Huang\, P
 rincipal Scientist and Head of In Vivo Pharmacology\, Simcere Innovation 
 Inc.\, Poonam Yakkundi\, Senior Scientist\, IGM Biosciences\, Regina Reil
 ly\, Research Fellow\, Abbvie\, Reshma Singh\, Head of Oncology Early Tra
 nslation\, Takeda Pharmaceuticals Co. Ltd.\, Robert Mihalek\, Principal S
 cientist and Associate Director - Pharmacology and Oncology\, Charles Riv
 er Laboratories\, Sreedhar Reddy Suthe\, Principal Scientist\, BrickBio\,
  Tamar Uziel\, Scientific Director\, Research Fellow\; Precision Medicine
  Oncology\, Translational Research\, Lead\, Abbvie\, Tapan Nayak\, Senior
  Director - Translational Imaging and Translational Medicine\, Merck and 
 Co\, Zohreh Amoozgar\, Pricipal Scientist and Lab Head\, Sanofi\n
DTEND:20240724T161000
DTSTAMP:20260512T220026Z
DTSTART:20240723T080000
LOCATION:The Westin Boston Seaport District\, 425\, Summer Street\, Boston
 \, Massachusetts\, 02210\,
SEQUENCE:0
SUMMARY:In the wake of the FDA Modernization Act and translational rates o
 f cancer drugs into the clinic at just 20%\, it is critical that oncology
  scientis...
UID:af876250-d7d9-4e01-a954-e4f72ebb917e
END:VEVENT
END:VCALENDAR